{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:00:40Z","timestamp":1788742840410,"version":"build-2803163510"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T00:00:00Z","timestamp":1401753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40259-014-0098-x","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T12:42:38Z","timestamp":1401712958000},"page":"487-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The Role of Interleukin-17A in Psoriatic Disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Silvano","family":"Adami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cavani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,3]]},"reference":[{"key":"98_CR1","unstructured":"Firestein GS, Corr M. Common mechanisms in immune-mediated inflammatory disease. J Rheumatol Suppl. 2005;73:8\u201313; discussion 29\u201330."},{"issue":"7","key":"98_CR2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1572-0241.2007.01215.x","volume":"102","author":"X Weng","year":"2007","unstructured":"Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern California-managed care organization. Am J Gastroenterol. 2007;102(7):1429\u201335. doi: 10.1111\/j.1572-0241.2007.01215.x .","journal-title":"Am J Gastroenterol."},{"key":"98_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3899\/jrheum.110907","volume":"88","author":"JT Rosenbaum","year":"2011","unstructured":"Rosenbaum JT, Russell AS, Guenther LC, El-Gabalawy H. The influence of uveitis on patients with immune-mediated inflammatory disease. J Rheumatol Suppl. 2011;88:26\u201330. doi: 10.3899\/jrheum.110907 .","journal-title":"J Rheumatol Suppl."},{"issue":"2","key":"98_CR4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1189\/JLB.0109046","volume":"86","author":"C Ortega","year":"2009","unstructured":"Ortega C, Fernandez AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009;86(2):435\u201343. doi: 10.1189\/JLB.0109046 .","journal-title":"J Leukoc Biol."},{"key":"98_CR5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev.pathol.4.110807.092254","volume":"4","author":"JB Imboden","year":"2009","unstructured":"Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol. 2009;4:417\u201334. doi: 10.1146\/annurev.pathol.4.110807.092254 .","journal-title":"Annu Rev Pathol."},{"issue":"6","key":"98_CR6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1468-3083.2006.01577.x","volume":"20","author":"J Pedraz","year":"2006","unstructured":"Pedraz J, Dauden E, Delgado-Jimenez Y, Garcia-Rio I, Garcia-Diez A. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin. J Eur Acad Dermatol Venereol. 2006;20(6):702\u20136. doi: 10.1111\/j.1468-3083.2006.01577.x .","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"5","key":"98_CR7","first-page":"625","volume":"2","author":"S Kuenzli","year":"2001","unstructured":"Kuenzli S, Saurat JH. Retinoids for the treatment of psoriasis: outlook for the future. Curr Opin Investig Drugs. 2001;2(5):625\u201330.","journal-title":"Curr Opin Investig Drugs."},{"issue":"4","key":"98_CR8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/157016309789869092","volume":"6","author":"M Kunz","year":"2009","unstructured":"Kunz M. Current treatment of psoriasis with biologics. Curr Drug Discov Technol. 2009;6(4):231\u201340.","journal-title":"Curr Drug Discov Technol."},{"issue":"2","key":"98_CR9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2133.1999.02976.x","volume":"141","author":"CM Clark","year":"1999","unstructured":"Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999;141(2):279\u201382.","journal-title":"Br J Dermatol."},{"issue":"1","key":"98_CR10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00128071-200001010-00003","volume":"1","author":"AL Kuijpers","year":"2000","unstructured":"Kuijpers AL, van de Kerkhof PC. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol. 2000;1(1):27\u201339.","journal-title":"Am J Clin Dermatol."},{"issue":"3","key":"98_CR11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.cyto.2008.07.017","volume":"43","author":"SL Gaffen","year":"2008","unstructured":"Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43(3):402\u20137. doi: 10.1016\/j.cyto.2008.07.017 .","journal-title":"Cytokine."},{"issue":"7","key":"98_CR12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nri2800","volume":"10","author":"DJ Cua","year":"2010","unstructured":"Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479\u201389. doi: 10.1038\/nri2800 .","journal-title":"Nat Rev Immunol."},{"key":"98_CR13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.2010.05825.x","volume":"1217","author":"Y Hu","year":"2011","unstructured":"Hu Y, Shen F, Crellin NK, Ouyang W. The IL-17 pathway as a major therapeutic target in autoimmune diseases. Ann N Y Acad Sci. 2011;1217:60\u201376. doi: 10.1111\/j.1749-6632.2010.05825.x .","journal-title":"Ann N Y Acad Sci."},{"issue":"4","key":"98_CR14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2133.2012.11099.x","volume":"167","author":"G Girolomoni","year":"2012","unstructured":"Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717\u201324. doi: 10.1111\/j.1365-2133.2012.11099.x .","journal-title":"Br J Dermatol."},{"key":"98_CR15","doi-asserted-by":"crossref","unstructured":"Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. doi: 10.1126\/scitranslmed.3001107 .","DOI":"10.1126\/scitranslmed.3001107"},{"issue":"5","key":"98_CR16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.micinf.2009.04.003","volume":"11","author":"P Miossec","year":"2009","unstructured":"Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect. 2009;11(5):625\u201330. doi: 10.1016\/j.micinf.2009.04.003 .","journal-title":"Microbes Infect."},{"issue":"10","key":"98_CR17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","volume":"11","author":"P Miossec","year":"2012","unstructured":"Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763\u201376. doi: 10.1038\/nrd3794 .","journal-title":"Nat Rev Drug Discov."},{"issue":"11","key":"98_CR18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1042\/CS20110496","volume":"122","author":"S Zhu","year":"2012","unstructured":"Zhu S, Qian Y. IL-17\/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2012;122(11):487\u2013511. doi: 10.1042\/CS20110496 .","journal-title":"Clin Sci (Lond)."},{"issue":"6","key":"98_CR19","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","volume":"129","author":"A Cesare Di","year":"2009","unstructured":"Di Cesare A, Di Meglio P, Nestle FO. The IL-23\/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339\u201350. doi: 10.1038\/jid.2009.59 .","journal-title":"J Invest Dermatol."},{"issue":"2","key":"98_CR20","first-page":"597","volume":"118","author":"HL Ma","year":"2008","unstructured":"Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118(2):597\u2013607. doi: 10.1172\/JCI33263 .","journal-title":"J Clin Invest."},{"issue":"3","key":"98_CR21","first-page":"318","volume":"4","author":"D Rosmarin","year":"2005","unstructured":"Rosmarin D, Strober BE. The potential of interleukin 12 inhibition in the treatment of psoriasis. J Drugs Dermatol. 2005;4(3):318\u201325.","journal-title":"J Drugs Dermatol."},{"issue":"1","key":"98_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section\u00a06. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137\u201374. doi: 10.1016\/j.jaad.2010.11.055 .","journal-title":"J Am Acad Dermatol."},{"issue":"Suppl 2","key":"98_CR23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1610-0387.2012.07919.x","volume":"10","author":"A Nast","year":"2012","unstructured":"Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. S3-Guidelines on the treatment of Psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10(Suppl 2):S1\u201395. doi: 10.1111\/j.1610-0387.2012.07919.x .","journal-title":"J Dtsch Dermatol Ges."},{"issue":"6","key":"98_CR24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2009.12.029","volume":"63","author":"K Reich","year":"2010","unstructured":"Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, et al. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol. 2010;63(6):1011\u20138. doi: 10.1016\/j.jaad.2009.12.029 .","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"98_CR25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1468-3083.2011.04044.x","volume":"26","author":"PP Lumig van","year":"2012","unstructured":"van Lumig PP, Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC, de Jong EM. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol. 2012;26(3):283\u201391. doi: 10.1111\/j.1468-3083.2011.04044.x .","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"3","key":"98_CR26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjd.12422","volume":"169","author":"M Esposito","year":"2013","unstructured":"Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666\u201372. doi: 10.1111\/bjd.12422 .","journal-title":"Br J Dermatol."},{"issue":"3","key":"98_CR27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/pch\/17.3.147","volume":"17","author":"N Saux Le","year":"2012","unstructured":"Le Saux N. Biologic response modifiers to decrease inflammation: focus on infection risks. Paediatr Child Health. 2012;17(3):147\u201354.","journal-title":"Paediatr Child Health."},{"issue":"5 Suppl 35","key":"98_CR28","first-page":"S108","volume":"22","author":"AK Imperato","year":"2004","unstructured":"Imperato AK, Bingham CO 3rd, Abramson SB. Overview of benefit\/risk of biological agents. Clin Exp Rheumatol. 2004;22(5 Suppl 35):S108\u201314.","journal-title":"Clin Exp Rheumatol."},{"issue":"4 Suppl","key":"98_CR29","first-page":"14","volume":"84","author":"A Menter","year":"2009","unstructured":"Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis. 2009;84(4 Suppl):14\u201324.","journal-title":"Cutis."},{"issue":"4","key":"98_CR30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ad.2012.10.018","volume":"104","author":"K Ortiz-Ibanez","year":"2013","unstructured":"Ortiz-Ibanez K, Alsina MM, Munoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr. 2013;104(4):304\u201310. doi: 10.1016\/j.adengl.2013.03.002 .","journal-title":"Actas Dermosifiliogr."},{"key":"98_CR31","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety\/tolerability of subcutaneous SCH 900222\/MK-3222 in participants with moderate-to-severe chronic plaque psoriasis (P07771\/MK-3222-011). 2013. http:\/\/www.clinicaltrials.gov\/show\/NCT01729754 . Accessed 25 Sept 2013."},{"key":"98_CR32","author":"B Strober","year":"2013","unstructured":"Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12\u00a0weeks of psoriasis treatment. Br J Dermatol. 2013. doi: 10.1111\/bjd.12517 .","journal-title":"Br J Dermatol."},{"issue":"3","key":"98_CR33","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","volume":"167","author":"KA Papp","year":"2012","unstructured":"Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668\u201377. doi: 10.1111\/j.1365-2133.2012.11168.x .","journal-title":"Br J Dermatol."},{"issue":"13","key":"98_CR34","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","volume":"366","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190\u20139. doi: 10.1056\/NEJMoa1109997 .","journal-title":"N Engl J Med."},{"issue":"13","key":"98_CR35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181\u20139. doi: 10.1056\/NEJMoa1109017 .","journal-title":"N Engl J Med."},{"issue":"2","key":"98_CR36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412\u201321. doi: 10.1111\/bjd.12110 .","journal-title":"Br J Dermatol."},{"issue":"5","key":"98_CR37","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section\u00a01. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350. doi: 10.1016\/j.jaad.2008.02.039 .","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"98_CR38","first-page":"50","volume":"1","author":"JA Zeichner","year":"2008","unstructured":"Zeichner JA. A practical approach to screening psoriasis patients for therapy with biologic agents. J Clin Aesthet Dermatol. 2008;1(3):50\u20134.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"2","key":"98_CR39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165\u201378. doi: 10.1136\/annrheumdis-2012-202545 .","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"98_CR40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","volume":"125","author":"T Dorner","year":"2010","unstructured":"Dorner T, Kinnman N. Tak PP. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther. 2010;125(3):464\u201375. doi: 10.1016\/j.pharmthera.2010.01.001 .","journal-title":"Pharmacol Ther."},{"issue":"5","key":"98_CR41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","volume":"31","author":"N Martin-Orozco","year":"2009","unstructured":"Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31(5):787\u201398. doi: 10.1016\/j.immuni.2009.09.014 .","journal-title":"Immunity."},{"key":"98_CR42","doi-asserted-by":"crossref","unstructured":"Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol. 2009;123(1):59\u201366 e4. doi: 10.1016\/j.jaci.2008.10.031 .","DOI":"10.1016\/j.jaci.2008.10.031"},{"issue":"4","key":"98_CR43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","volume":"194","author":"P Ye","year":"2001","unstructured":"Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194(4):519\u201327.","journal-title":"J Exp Med."},{"issue":"6","key":"98_CR44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cytogfr.2010.10.006","volume":"21","author":"K Hirahara","year":"2010","unstructured":"Hirahara K, Ghoreschi K, Laurence A, Yang XP, Kanno Y, O\u2019Shea JJ. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev. 2010;21(6):425\u201334. doi: 10.1016\/j.cytogfr.2010.10.006 .","journal-title":"Cytokine Growth Factor Rev."},{"key":"98_CR45","author":"VP Parachuru","year":"2014","unstructured":"Parachuru VP, Coates DE, Milne TJ, Hussaini HM, Rich AM, Seymour GJ. Forkhead box P3-positive regulatory T-cells and interleukin 17-positive T-helper 17 cells in chronic inflammatory periodontal disease. J Periodontal Res. 2014. doi: 10.1111\/jre.12169 .","journal-title":"J Periodontal Res."},{"key":"98_CR46","doi-asserted-by":"crossref","unstructured":"Corneth OB, Mus AM, Asmawidjaja PS, Klein Wolterink RG, van Nimwegen M, Brem MD et al. Absence of interleukin-17 receptor A signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. Arthritis Rheumatol. 2014;66(2):340\u20139. doi: 10.1002\/art.38229 .","DOI":"10.1002\/art.38229"},{"issue":"9","key":"98_CR47","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.4049\/jimmunol.0901767","volume":"184","author":"D Pennino","year":"2010","unstructured":"Pennino D, Eyerich K, Scarponi C, Carbone T, Eyerich S, Nasorri F, et al. IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. J Immunol. 2010;184(9):4880\u20138. doi: 10.4049\/jimmunol.0901767 .","journal-title":"J Immunol."},{"issue":"7446","key":"98_CR48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature11981","volume":"496","author":"N Yosef","year":"2013","unstructured":"Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature. 2013;496(7446):461\u20138. doi: 10.1038\/nature11981 .","journal-title":"Nature."},{"issue":"5","key":"98_CR49","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.micinf.2009.04.007","volume":"11","author":"JJ O\u2019Shea","year":"2009","unstructured":"O\u2019Shea JJ, Steward-Tharp SM, Laurence A, Watford WT, Wei L, Adamson AS, et al. Signal transduction and Th17 cell differentiation. Microbes Infect. 2009;11(5):599\u2013611. doi: 10.1016\/j.micinf.2009.04.007 .","journal-title":"Microbes Infect."},{"issue":"25","key":"98_CR50","doi-asserted-by":"crossref","first-page":"17003","DOI":"10.1074\/jbc.M801286200","volume":"283","author":"K Ichiyama","year":"2008","unstructured":"Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem. 2008;283(25):17003\u20138. doi: 10.1074\/jbc.M801286200 .","journal-title":"J Biol Chem."},{"issue":"9","key":"98_CR51","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888\u201398. doi: 10.1056\/NEJMra0707449 .","journal-title":"N Engl J Med."},{"key":"98_CR52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485\u2013517. doi: 10.1146\/annurev.immunol.021908.132710 .","journal-title":"Annu Rev Immunol."},{"issue":"6","key":"98_CR53","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/ni0608-588","volume":"9","author":"A O\u2019Garra","year":"2008","unstructured":"O\u2019Garra A, Stockinger B, Veldhoen M. Differentiation of human T(H)-17 cells does require TGF-beta!. Nat Immunol. 2008;9(6):588\u201390. doi: 10.1038\/ni0608-588 .","journal-title":"Nat Immunol."},{"issue":"6","key":"98_CR54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.smim.2007.10.015","volume":"19","author":"Z Chen","year":"2007","unstructured":"Chen Z, Laurence A, O\u2019Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol. 2007;19(6):400\u20138. doi: 10.1016\/j.smim.2007.10.015 .","journal-title":"Semin Immunol."},{"issue":"4","key":"98_CR55","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","volume":"35","author":"Y Cai","year":"2011","unstructured":"Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity. 2011;35(4):596\u2013610. doi: 10.1016\/j.immuni.2011.08.001 .","journal-title":"Immunity."},{"issue":"5","key":"98_CR56","doi-asserted-by":"crossref","first-page":"e62231","DOI":"10.1371\/journal.pone.0062231","volume":"8","author":"M Katayama","year":"2013","unstructured":"Katayama M, Ohmura K, Yukawa N, Terao C, Hashimoto M, Yoshifuji H, et al. Neutrophils are essential as a source of IL-17 in the effector phase of arthritis. PLoS One. 2013;8(5):e62231. doi: 10.1371\/journal.pone.0062231 .","journal-title":"PLoS One."},{"issue":"5","key":"98_CR57","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.coi.2011.07.006","volume":"23","author":"SL Gaffen","year":"2011","unstructured":"Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011;23(5):613\u20139. doi: 10.1016\/j.coi.2011.07.006 .","journal-title":"Curr Opin Immunol."},{"issue":"2","key":"98_CR58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10875-010-9369-6","volume":"30","author":"R Pappu","year":"2010","unstructured":"Pappu R, Ramirez-Carrozzi V, Ota N, Ouyang W, Hu Y. The IL-17 family cytokines in immunity and disease. J Clin Immunol. 2010;30(2):185\u201395. doi: 10.1007\/s10875-010-9369-6 .","journal-title":"J Clin Immunol."},{"issue":"8","key":"98_CR59","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"SL Gaffen","year":"2009","unstructured":"Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556\u201367. doi: 10.1038\/nri2586 .","journal-title":"Nat Rev Immunol."},{"key":"98_CR60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0083-6729(06)74010-9","volume":"74","author":"SL Gaffen","year":"2006","unstructured":"Gaffen SL, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm. 2006;74:255\u201382. doi: 10.1016\/S0083-6729(06)74010-9 .","journal-title":"Vitam Horm."},{"issue":"9","key":"98_CR61","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.4049\/jimmunol.1102576","volume":"187","author":"SL Gaffen","year":"2011","unstructured":"Gaffen SL. Life before seventeen: cloning of the IL-17 receptor. J Immunol. 2011;187(9):4389\u201391. doi: 10.4049\/jimmunol.1102576 .","journal-title":"J Immunol."},{"issue":"3","key":"98_CR62","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pros.10238","volume":"56","author":"GE Steiner","year":"2003","unstructured":"Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56(3):171\u201382. doi: 10.1002\/pros.10238 .","journal-title":"Prostate."},{"issue":"1","key":"98_CR63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1523-1747.2000.00041.x","volume":"115","author":"C Albanesi","year":"2000","unstructured":"Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol. 2000;115(1):81\u20137. doi: 10.1046\/j.1523-1747.2000.00041.x .","journal-title":"J Invest Dermatol."},{"issue":"3","key":"98_CR64","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/cmi.2010.21","volume":"7","author":"S Xu","year":"2010","unstructured":"Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. 2010;7(3):164\u201374. doi: 10.1038\/cmi.2010.21 .","journal-title":"Cell Mol Immunol."},{"issue":"5","key":"98_CR65","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/ar4071","volume":"14","author":"MS Doyle","year":"2012","unstructured":"Doyle MS, Collins ES, Fitzgerald OM, Pennington SR. New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis. Arthritis Res Ther. 2012;14(5):226. doi: 10.1186\/ar4071 .","journal-title":"Arthritis Res Ther."},{"issue":"3","key":"98_CR66","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2249.2002.01782.x","volume":"127","author":"A Kehlen","year":"2002","unstructured":"Kehlen A, Thiele K, Riemann D, Langner J. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol. 2002;127(3):539\u201346.","journal-title":"Clin Exp Immunol."},{"issue":"9","key":"98_CR67","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.4049\/jimmunol.176.9.5652","volume":"176","author":"ML Cho","year":"2006","unstructured":"Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol. 2006;176(9):5652\u201361.","journal-title":"J Immunol."},{"issue":"37","key":"98_CR68","doi-asserted-by":"crossref","first-page":"27229","DOI":"10.1074\/jbc.M703250200","volume":"282","author":"DN Patel","year":"2007","unstructured":"Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A, et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1\/2-dependent NF-kappaB and C\/EBPbeta activation. J Biol Chem. 2007;282(37):27229\u201338. doi: 10.1074\/jbc.M703250200 .","journal-title":"J Biol Chem."},{"issue":"12","key":"98_CR69","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.cellsig.2013.07.021","volume":"25","author":"X Song","year":"2013","unstructured":"Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal. 2013;25(12):2335\u201347. doi: 10.1016\/j.cellsig.2013.07.021 .","journal-title":"Cell Signal."},{"issue":"2","key":"98_CR70","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0625.2011.01412.x","volume":"21","author":"D Gutowska-Owsiak","year":"2012","unstructured":"Gutowska-Owsiak D, Schaupp AL, Salimi M, Selvakumar TA, McPherson T, Taylor S, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21(2):104\u201310. doi: 10.1111\/j.1600-0625.2011.01412.x .","journal-title":"Exp Dermatol."},{"key":"98_CR71","author":"H Kato","year":"2013","unstructured":"Kato H, Endres J, Fox DA. The roles of IFN-gamma versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. Mod Rheumatol. 2013. doi: 10.1007\/s10165-012-0811-x .","journal-title":"Mod Rheumatol."},{"issue":"1","key":"98_CR72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","volume":"52","author":"A Russolillo","year":"2013","unstructured":"Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford). 2013;52(1):62\u20137. doi: 10.1093\/rheumatology\/kes242 .","journal-title":"Rheumatology (Oxford)."},{"issue":"5","key":"98_CR73","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/157016112801784567","volume":"10","author":"AV Marzano","year":"2012","unstructured":"Marzano AV, Tedeschi A, Polloni I, Crosti C, Cugno M. Interactions between inflammation and coagulation in autoimmune and immune-mediated skin diseases. Curr Vasc Pharmacol. 2012;10(5):647\u201352.","journal-title":"Curr Vasc Pharmacol."},{"issue":"5","key":"98_CR74","first-page":"1092","volume":"159","author":"KE Nograles","year":"2008","unstructured":"Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092\u2013102. doi: 10.1111\/j.1365-2133.2008.08769.x .","journal-title":"Br J Dermatol."},{"issue":"3","key":"98_CR75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/08916930903510906","volume":"43","author":"C Albanesi","year":"2010","unstructured":"Albanesi C, Scarponi C, Bosisio D, Sozzani S, Girolomoni G. Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity. 2010;43(3):215\u20139. doi: 10.3109\/08916930903510906 .","journal-title":"Autoimmunity."},{"issue":"13","key":"98_CR76","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","volume":"204","author":"LC Zaba","year":"2007","unstructured":"Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183\u201394. doi: 10.1084\/jem.20071094 .","journal-title":"J Exp Med."},{"issue":"1","key":"98_CR77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4049\/jimmunol.162.1.494","volume":"162","author":"C Albanesi","year":"1999","unstructured":"Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol. 1999;162(1):494\u2013502.","journal-title":"J Immunol."},{"issue":"3","key":"98_CR78","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4049\/jimmunol.1001001","volume":"186","author":"HL Rizzo","year":"2011","unstructured":"Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186(3):1495\u2013502. doi: 10.4049\/jimmunol.1001001 .","journal-title":"J Immunol."},{"key":"98_CR79","doi-asserted-by":"crossref","unstructured":"Schett G. Joint remodelling in inflammatory disease. Ann Rheum Dis. 2007;66 Suppl 3:iii42\u20134. doi: 10.1136\/ard.2007.078972 .","DOI":"10.1136\/ard.2007.078972"},{"key":"98_CR80","doi-asserted-by":"crossref","unstructured":"de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes\u2014what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011;50(1):93\u2013100. doi: 10.1093\/rheumatology\/keq230 .","DOI":"10.1093\/rheumatology\/keq230"},{"issue":"1","key":"98_CR81","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar2936","volume":"12","author":"IE Adamopoulos","year":"2010","unstructured":"Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010;12(1):R29. doi: 10.1186\/ar2936 .","journal-title":"Arthritis Res Ther."},{"issue":"8","key":"98_CR82","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/1381612013397807","volume":"7","author":"PJ Kostenuik","year":"2001","unstructured":"Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des. 2001;7(8):613\u201335.","journal-title":"Curr Pharm Des."},{"issue":"6937","key":"98_CR83","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337\u201342. doi: 10.1038\/nature01658 .","journal-title":"Nature."},{"issue":"10","key":"98_CR84","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1359\/JBMR.050601","volume":"20","author":"M Stolina","year":"2005","unstructured":"Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res. 2005;20(10):1756\u201365. doi: 10.1359\/JBMR.050601 .","journal-title":"J Bone Miner Res."},{"issue":"11","key":"98_CR85","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","volume":"146","author":"T Bellido","year":"2005","unstructured":"Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O\u2019Brien CA, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):4577\u201383. doi: 10.1210\/en.2005-0239 .","journal-title":"Endocrinology."},{"issue":"2","key":"98_CR86","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156\u201363. doi: 10.1038\/nm1538 .","journal-title":"Nat Med."},{"issue":"12","key":"98_CR87","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/ard.61.12.1047","volume":"61","author":"TN Crotti","year":"2002","unstructured":"Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis. 2002;61(12):1047\u201354.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"98_CR88","first-page":"1407","volume":"123","author":"YY Liu","year":"2010","unstructured":"Liu YY, Long L, Wang SY, Guo JP, Ye H, Cui LF, et al. Circulating Dickkopf-1 and osteoprotegerin in patients with early and longstanding rheumatoid arthritis. Chin Med J (Engl). 2010;123(11):1407\u201312.","journal-title":"Chin Med J (Engl)."},{"issue":"12","key":"98_CR89","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.4049\/jimmunol.0903719","volume":"184","author":"TP Singh","year":"2010","unstructured":"Singh TP, Schon MP, Wallbrecht K, Michaelis K, Rinner B, Mayer G, et al. 8-Methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23\/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol. 2010;184(12):7257\u201367. doi: 10.4049\/jimmunol.0903719 .","journal-title":"J Immunol."},{"issue":"1","key":"98_CR90","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2011.06.037","volume":"67","author":"JE Gudjonsson","year":"2012","unstructured":"Gudjonsson JE, Johnston A, Ellis CN. Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol. 2012;67(1):139\u201347. doi: 10.1016\/j.jaad.2011.06.037 .","journal-title":"J Am Acad Dermatol."},{"key":"98_CR91","doi-asserted-by":"crossref","unstructured":"Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72 Suppl 2:ii116\u201323. doi: 10.1136\/annrheumdis-2012-202371 .","DOI":"10.1136\/annrheumdis-2012-202371"},{"issue":"2","key":"98_CR92","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","volume":"168","author":"P Rich","year":"2013","unstructured":"Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402\u201311. doi: 10.1111\/bjd.12112 .","journal-title":"Br J Dermatol."},{"issue":"6","key":"98_CR93","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","volume":"72","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72(6):863\u20139. doi: 10.1136\/annrheumdis-2012-201601 .","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"98_CR94","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.4049\/jimmunol.1001153","volume":"185","author":"S Kagami","year":"2010","unstructured":"Kagami S, Rizzo HL, Kurtz SE, Miller LS, Blauvelt A. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol. 2010;185(9):5453\u201362. doi: 10.4049\/jimmunol.1001153 .","journal-title":"J Immunol."},{"key":"98_CR95","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2013. doi: 10.1136\/annrheumdis-2012-202646 .","journal-title":"Ann Rheum Dis."},{"key":"98_CR96","doi-asserted-by":"crossref","unstructured":"Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777\u201387. doi: 10.1016\/j.ophtha.2012.09.040 .","DOI":"10.1016\/j.ophtha.2012.09.040"},{"key":"98_CR97","author":"P Rich","year":"2012","unstructured":"Rich P, Sigurgeirsson B, Thaci DP, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2012. doi: 10.1111\/bjd.12070 .","journal-title":"Br J Dermatol."},{"issue":"12","key":"98_CR98","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700. doi: 10.1136\/gutjnl-2011-301668 .","journal-title":"Gut."},{"key":"98_CR99","author":"M Her","year":"2013","unstructured":"Her M, Kavanaugh A. Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors. Curr Opin Rheumatol. 2013. doi: 10.1097\/BOR.0b013e3283620177 .","journal-title":"Curr Opin Rheumatol."},{"issue":"4","key":"98_CR100","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2340\/00015555-1376","volume":"92","author":"MW Meyer","year":"2012","unstructured":"Meyer MW, Zachariae C, Bendtzen K, Skov L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm Venereol. 2012;92(4):362\u20134. doi: 10.2340\/00015555-1376 .","journal-title":"Acta Derm Venereol."},{"issue":"12","key":"98_CR101","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1358\/dof.2012.037.012.1915459","volume":"37","author":"Z Gajdosik","year":"2012","unstructured":"Gajdosik Z. Brodalumab (AMG-827). Drugs Fut. 2012;37(12):837.","journal-title":"Drugs Fut."},{"issue":"11","key":"98_CR102","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","volume":"188","author":"WW Busse","year":"2013","unstructured":"Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294\u2013302. doi: 10.1164\/rccm.201212-2318OC .","journal-title":"Am J Respir Crit Care Med."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-014-0098-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-014-0098-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-014-0098-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T21:27:11Z","timestamp":1689283631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-014-0098-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,3]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["98"],"URL":"https:\/\/doi.org\/10.1007\/s40259-014-0098-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,3]]}}}